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Abstract The Impella percutaneous mechanical cir-
culatory support device is designed to augment car-
diac output and reduce left ventricular wall stress and
aims to improve survival in cases of cardiogenic shock.
In this meta-analysis we investigated the haemody-
namic effects of the Impella device in a clinical setting.
We systematically searched all articles in PubMed/
Medline and Embase up to July 2019. The primary
outcomes were cardiac power (CP) and cardiac power
index (CPI). Survival rates and other haemodynamic
data were included as secondary outcomes. For the
critical appraisal, we used a modified version of the
U.S. Department of Health and Human Services qual-
ity assessment form. The systematic review included
12 studies with a total of 596 patients. In 258 patients
the CP and/or CPI could be extracted. Our meta-anal-
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ysis showed an increase of 0.39W [95% confidence in-
terval (CI): 0.24, 0.54], (p= 0.01) and 0.22W/m2 (95%
CI: 0.18, 0.26), (p<0.01) for the CP and CPI, respec-
tively. The overall survival rate was 56% (95% CI: 0.50,
0.62), (p=0.09). The quality of the studies was moder-
ate, mostly due to the presence of confounders. Our
study suggests that in patients with cardiogenic shock,
Impella support seems effective in augmenting CP(I).
This study merely investigates the haemodynamic ef-
fectiveness of the Impella device and does not reflect
the complete clinical impact for the patient.
Keywords Impella · Haemodynamic monitoring ·
Cardiogenic shock · Heart failure · Left ventricular
assist device
Introduction
The Impella (Abiomed, Danvers, MA, USA) is a percu-
taneous mechanical circulatory support (MCS) device
consisting of a non-pulsatile microaxial flow pump
based on the Archimedes screw principle that propels
blood from the left ventricle into the ascending aorta.
Aside from increasing blood flow, the Impella device
aims to reduce ventricular wall stress, thereby unload-
ing the left ventricle, reducing oxygen consumption
and decreasing infarct size [1]. A series of Impella de-
vices are available for left ventricular support. The
Impella 2.5 and Impella CP can provide haemody-
namic support up to 2.5 and 3.7 l/min, respectively.
The strongest Impella, the Impella 5.0, can deliver up
to 5 l/min of haemodynamic support. However, this
includes the use of a 21Fr pump motor, making the
implantation in the acute setting more challenging [2,
3].
MCS devices have been increasingly used as a key
element in the management of patients with cardio-
genic shock (CS) [4]. Based on the results of the US-
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pella Registry, which showed a significant increase
of cardiac output (CO) [5], the Impella received FDA
approval in 2016 for the treatment of CS. Increased
flow is beneficial in CS, since low CO and reduced
perfusion pressure are the bases of CS syndrome [6].
However, these two factors are intertwined, and a de-
creased output does not necessarily indicate a de-
creased perfusion pressure and vice versa. The prod-
uct of these combined parameters is the cardiac power
(CP), and is the strongest haemodynamic predictor of
mortality in the SHOCK trial registry [7]. This find-
ing was confirmed in a more recent study, where the
cardiac power index (CPI) was found to be the best
haemodynamic predictor of survival in a CS popula-
tion [8].
As CP and CPI are the best predictors for survival,
we focused specifically on the effects of Impella on
CP(I).
Methods
We performed a systematic review and meta-analysis
on the haemodynamic effects of the Impella during
CS. Survival rate was a secondary outcome.
Search strategy
Medical literature databases PubMed/Medline and
Embase were searched using the following keywords:
(((Impella[tiab] OR (microaxial[tiab] OR axial[tiab])
AND flow[tiab] AND (pump*[tiab] OR catheter*[tiab])
OR percutaneous left ventricular assist device*[tiab]))
AND (((cardiogenic shock[tiab] OR cardiac shock[tiab]
OR cardiovascular shock[tiab] OR heart shock[tiab]
OR acute cardiac failure[tiab] OR acute decom-
pensated heart failure[tiab] OR acute heart insuf-
ficiency[tiab] OR acutely decompensated heart fail-
ure[tiab] OR ADHF[tiab] OR forward heart failure[tiab]
OR low cardiac output[tiab] OR low output syn-
drome[tiab] OR systolic dysfunction[tiab])) OR
(((Shock, Cardiogenic[Mesh] OR Heart Failure[Mesh:
noexp] OR Heart Failure, Systolic[Mesh])) OR “My-
ocardial Infarction”[Mesh]))). A methodological filter
was used to limit the results to adult humans. The
search was last updated on 9 July 2019.
Inclusion and exclusion criteria
This article is in accordance with the PRISMA guide-
lines (see Electronic Supplementary Material for
checklist, online Table 1) [9]. Studies eligible for
inclusion were original articles that met the follow-
ing criteria: retrospective, prospective cohort studies
and randomised controlled trials in CS patients, with
a reported CS. We excluded letters, case reports and
studies that focused on high-risk percutaneous coro-
nary intervention (PCI). No further restrictions on
publication date, status or language were imposed.
The search was then loaded into Endnote X8 and
possible duplicates were deleted. The two review-
ers independently reviewed all titles, abstracts and
manuscripts to determine whether they met the in-
clusion criteria. Disagreement between reviewers (K.P.
and D.D.) was resolved by consensus. Reference lists
from eligible studies were checked to identify addi-
tional studies and citations. For the critical appraisal,
we used an adapted version of the U.S. Department of
Health and Human Services quality assessment form
(see Fig. 6; [10]).
Both reviewers independently extracted the data
from all the selected manuscripts. For haemodynamic
parameters the CO, cardiac index (CI), mean arte-
rial pressure (MAP), CP, CPI and pulmonary wedge
pressure (PWP) were obtained. For non-haemody-
namic parameters, type and duration of MCS, me-
chanical ventilation, cardiopulmonary resuscitation,
gender and survival were also extracted from the in-
dividual studies.
Outcomes
Primary outcomes were CP and CPI. The CP is calcu-
lated as: CO×MAP/451 [7]. The CPI was computed by
substituting CO with CI in the respective formula.
Secondary outcomes included survival, type and
duration of MCS, mechanical ventilation, cardiopul-
monary resuscitation, gender and other haemody-
namic data (CO, CI, MAP, PWP).
Statistical analysis
All data were analysed using Review Manager 5.3.5
and Rstudio. Categorical variables were presented as
percentages. Continuous variables were presented as
range or mean± standard deviation (SD). For continu-
ous variables reported as median± interquartile range,
the mean and SD were estimated by using the formula
as proposed by Hozo et al. [11]. Not all studies men-
tioned the CP or CPI directly; therefore the missing CP
or CPI and accessory SD were calculated according to
the appropriate formulas [11].
Heterogeneity defined as variation among the re-
sults of the individual studies was assessed with
Cochrane’s Q-statistic (pchance and I2 statistic). Ran-
dom effects models were used to calculate mean
pooled differences of haemodynamic data between
baseline and Impella support for CP and CPI. A sub-
group analysis of the Impella 2.5 and 5.0 was made.
For survival rates, the overall proportion from studies
reporting a single proportion was calculated. Note
that since not all variables were measured in all pa-
tients and all studies, the number of patients and
studies per meta-analysis is different.
Results
Study characteristics
Our systematic literature search in PubMed/Medline
and Embase resulted in 946 records (Fig. 1). After ex-
clusion, 12 articles (including 1 via cross-reference) re-
mained for qualitative and quantitative synthesis and
meta-analysis [5, 12–22]. Nine of the 12 studies were
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observational. Two were prospective single-arm tri-
als and one study was a randomised controlled trial.
The Impella 2.5 was investigated in five studies, the
Impella 5.0 in six studies and one study investigated
both devices.
Patients
The systematic review included 12 studies with a to-
tal of 596 patients studied. Patient characteristics are
shown in Tab. 1.
Indications for Impella implant were CS after acute
myocardial infarction (CS-AMI) in 380 (64%), end-
stage heart failure in 96 (16%) and post-cardiac
surgery in 30 patients (5%). The remaining 88 (15%)
patients had Impella implanted for various causes of
CS.
During hospital admission, 55–100% of the patients
received mechanical ventilation and 49–85% had car-
diopulmonary resuscitation prior to Impella implan-
tation. In all studies, patients were pharmacologically
supported by inotropic and/or vasopressor agents and
in 9 of the 12 studies (74% of all patients) PCI was
conducted. The mean duration of support with the
Impella was 0.9–12 days.
Meta-analysis
CO and/or CI were reported in 258 (43%) patients
(see Tab. 1). Using a random effect model, use of
the Impella led to an increase in CP of 0.39W [95%
confidence interval (CI): 0.24, 0.54], (p=0.01) and CPI
0.22W/m2 (95% CI: 0.18, 0.26), (p<0.01); see Tab. 2
and Fig. 2.
Use of the Impella 2.5 showed a mean pooled in-
crease in CP and CPI of 0.29W (95% CI: –0.02, 0.59),
(p= 0.07), +48% and 0.18W/m2 (95% CI: 0.06, 0.29),
(p< 0.01), +58%, respectively. Use of the Impella 5.0
led to a mean pooled increase in CP and CPI of 0.46W
(95% CI: 0.35, 0.58), (p<0.01), +82% and 0.27W/m2
(95% CI: 0.17, 0.38), (p< 0.01), +102%. See Electronic
Supplementary Material, online Figs. 1 and 2.
The majority of the patients received an Impella
for CS after an AMI, which comprised 63% of the total
study population. When analysing the AMI-CS specif-
ically, the CPI increase was similar to that of the whole
group (n= 258). See Electronic Supplementary Mate-
rial, online Fig. 3.
Themean survival rate was 56% (95% CI: 0.50, 0.62),
(p= 0.09), see Fig. 3. MAP increased with a pooled
mean difference of 13mmHg (95% CI: 3.74, 22.98),
(p< 0.01). PWP decreased when the Impella was used
Haemodynamic efficacy of microaxial left ventricular assist device in cardiogenic shock: a systematic review. . .
Review Article
Table 1 Study characteristics included in the meta-analysis
Study Year Study type Number of
patients
Type of
Impella
Indication CS-AMI Age
(years)
Male
(%)
MV
(%)
CPR
(%)
Support
(days)
LVEF
(%)
Meyns [12] 2003 Registry 13 5.0 CS 6/16 60± n.a. 69 – – 4.0± n.a. –
Dens [13] 2006 Prospective 11 2.5 CS-AMI 11 61± 11 73 – – 0.9± 0.7 29± 11
Seyfarth [14] 2008 RCT 13 2.5 CS-AMI 13 65± 10 62 92 85 0.9± 0.8 27± n.a.
Bresson [15] 2011 Registry 5 (9) 5.0 CS 6/11 50± 14 83 100 – 12± 7.3 –
Griffith [16] 2013 Prospective 16 5.0 CS* 0/16 58± 9 81 – – 3.7± 2.9 23± 7
O’Neill [5] 2014 Registry 23 (154) 2.5 CS-AMI 154 64± 13 71 66 49 1.2± 1.9 26± 13
Casassus [17] 2015 Registry 9 (22) 2.5 CS-AMI 22 58± 12 59 55 55 1.5± 1.1 27± 8
Lima [18] 2016 Registry 21 (40) 5.0 ESHF 0/40 55± 13 78 65 – 7± 5 12± 5
Schiller [19] 2016 Registry 66 2.5/5.0 CS 26/66 55± 2 65 – – 7.4± 0.8 28± 14
Joseph [20] 2016 Registry 35 (180) 2.5 CS-AMI 180 66± 13 73 77 55 n.a. 26± 12
Mastroianni [21] 2017 Registry 14 5.0 CS* 0/14 64± 15 79 71 – 8.5± 4.7 –
Hall [22] 2018 Observational 58 5.0 ESHF 0/58 55± 13 79 24 – 7± 5 13± 7
CS-AMI cardiogenic shock complicating acute myocardial infarction; CS* cardiogenic shock post-surgery; ESHF end-stage heart failure; MV mechanical
ventilation; CPR cardiopulmonary resuscitation; LVEF left ventricular ejection fraction; – not available
Table 2 Individual study results of haemodynamic support and survival
Study Type of
device
CP
(W)
CPI
(W/m2)
CO
(l/min)
CI
(l/min/m2)
MAP
(mmHg)
Survival
(%)
Baseline Support Baseline Support Baseline Support Baseline Support Baseline Support
Meyns [12] 5.0 0.52± 0.20 0.91± 0.27 – – 4.1± 1.3 5.5± 1.3 – – 57± 13 75± 13 46
Dens [13] 2.5 0.85± 0.46 0.84± 0.27 – – 4.4± 1.9 4.8± 1.2 – – 87± 25 79± 16 55
Seyfarth [14] 2.5 0.55± 0.18 0.79± 0.28 0.30± 0.12 0.42± 0.15 3.2± 0.8 4.1± 1.2 1.7± 0.5 2.2± 0.6 78± 16 87± 8 54
Bresson [15] 5.0 0.64± 0.07 0.94± 0.44 – – 4± 0.55 5.9± 2.7 – – – – 44
Griffith [16] 5.0 – – 0.25± 0.07 0.46± 0.08 – – 1.6± 0.4 2.5± 0.4 71± 13 83± 7.5 75
O’Neill [5] 2.5 0.48± 0.17 1.06± 0.48 0.26± 0.13 0.57± 0.20 3.4± 1.3 5.3± 1.7 1.9± 0.7 2.7± 0.7 63± 19 94± 23 51
Casassus [17] 2.5 – – 0.33± 0.10 0.49± 0.20 – – 2.2± 0.4 2.6± 0.7 67± 15 82± 13 59
Lima [18] 5.0 0.54± 0.17 1.18± 0.61 0.28± 0.09 0.52± 0.18 3.7± 1.3 5.8± 1.4 1.8± 0.5 2.9± 0.7 71± 11 82± 20 68
Schiller [19] 2.5/5.0 0.66± 0.2 – 0.36± 0.03 0.62± 0.04 – – 2.2± 0.2 3.8± 0.2 73± 2 73± 2 58
Joseph [20] 2.5 – – 0.27± 0.15 0.46± 0.20 3.5± 1.3 – 2.0± 0.6 2.4± 0.8 60± 28 87± 27 44
Mastroianni [21] 5.0 – – 0.21± 0.06 0.46± 0.08 – – 1.6± 0.4 2.8± 0.3 60± 9 74± 9 57
Hall [22] 5.0 0.6± 0.3 1.1± 0.5 – – 3.7± 1.9 – 1.8± 0.6 2.8± 0.6 70± 11 – 67
Variables are presented as mean± SD
CO cardiac output; CI cardiac index; MAP mean arterial pressure; CP cardiac power; CPI cardiac power index; W Watt; – not available
with a mean pooled difference of –8.30mmHg (95%
CI: –10.63, –6.06), (p<0.01). See Tab. 2, Figs. 4 and 5
and Electronic Supplementary Material.
Critical appraisal
One study was considered of sufficiently good quality
to show that Impella support results in increased CP
and CPI [14]. Overall studies were considered to be
of moderate quality, mostly due to lack of description
of confounders and data acquisition protocol. On the
other hand, all studies were comparable in terms of
outcomes, study design, study population and type of
support, which allowed us to conduct a meta-analysis
(see Fig. 6).
Discussion
To our knowledge, this is the first meta-analysis that
has focused on the increase in CP and CPI during Im-
pella support. This meta-analysis, including 258 pa-
tients from 12 studies, showed that the use of the Im-
pella device significantly increases the CP by 0.39W
(+67%) and CPI by 0.22W/m2 (+76%). When compar-
ing the different Impella devices, the Impella 2.5 in
general achieves a lower performance relative to the
Impella 5.0 in both CP (+48% vs +82%) and CPI (+58%
vs +102%).
The observed increase in CP(I) during Impella sup-
port, which has been shown to be a strong haemody-
namic predictor of survival in CS [7, 8], should theo-
retically lead to a reduction in mortality. Extrapolating
from the survival graph of Fincke et al., the increase of
CP from 0.5W to 0.9W should decrease mortality from
approximately 50% to 20% [7]. The overall percent-
age survival in our meta-analysis, 56%, is in line with
two small randomised controlled trials [14, 23] and
a propensity-matched analysis [24], which all com-
pared the Impella CP to passive unloading with the
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Fig. 2 Forest plot of a cardiac power (CP) and b cardiac power index
Fig. 3 Forest plot of sur-
vival
intra-aortic balloon pump. This indicates that the re-
lationship between (mechanical) haemodynamic im-
provement and survival is less evident than suggested.
In our study we focused mainly on CS after AMI
(64% in our analysis). However, CS has a broad scope
of aetiology. In some very specific indications, such
as a biopsy-proven myocarditis, there is growing evi-
dence of improved survival with Impella support [25].
In other indications for Impella support, such as the
post-cardiotomy population (5% in our study), evi-
dence is still limited and in need of further research.
However, small registries show survival rates compa-
rable with those of more invasive assist devices, such
as surgically implantable ventricular assist devices
[26]. Therefore, patient selection in terms of cause
and reversibility of cause is an important determinant
of survival in CS.
Within the CS-AMI group, patient selection might
be an explanation for the lack of a clear survival bene-
fit with improved haemodynamics. Patients with a rel-
atively preserved cardiac function seem to have the
best chance of survival and show a better haemody-
namic improvement [27]. In patients who have no car-
diac reserve, the intrinsic CP is unchanged and thus
remains the Achilles’ heel of survival. Only when the
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Fig. 4 Forest plot of mean arterial pressure (MAP)
Fig. 5 Forest plot of pulmonary wedge pressure (PWP)
affected myocardium is able to recover can the intrin-
sic CP increase and thereby improve outcome.
To achieve recovery of the myocardium Impella
provides unloading, represented by a significant de-
crease of the PWP by 8mmHg in our meta-analysis.
This clearly distinguishes mechanical support with
the Impella device from medical therapy (inotropic
or vasoactive agents), which increases the workload
of the heart in order to improve the CPI [28]. Un-
loading of the left ventricle leads to reduced oxygen
consumption and should thereby reduce infarct size
in patients with CS-AMI. Animal studies have shown
that unloading does reduce infarct size [1, 29], espe-
cially when support is started at an early stage. How-
ever, the clinical trial which investigated if unloading
with Impella support would reduce the infarct size
(MINI-AMI, Minimizing Infarct Size with Impella 2.5
Following PCI for Acute Myocardial Infarction, Clini-
calTrials.gov identifier NCT01319760) was terminated
due to a ‘change in company priority’. This raises
questions as to whether the study was able to show
positive results.
In terms of the timing of support, several studies
suggest that early implantation of a mechanical as-
sist device would improve survival [30–32]. Recent
extensive animal studies showed that mechanical un-
loading of the left ventricle before coronary reper-
fusion limits the expression of proteolytic enzymes.
This resulted in less cell decay, reduced infarction size
and better haemodynamic performance [33]. A recent
clinical trial also showed promising results when the
Impella support was initiated before emergency PCI
[34]. This is in contrast to our meta-analysis, in which
support was given after almost 3 days after the onset
of CS. The late initiation of supportmight preclude the
potential benefit to survival rates. On the other hand,
real-world data are refractory. In the 12-year experi-
ence of the Amsterdam Medical Centre there was no
significant improvement of survival when support was
initiated before PCI [35].
Clinical and future perspectives
In the critical setting of CS, the Impella device im-
proves the haemodynamic state and relieves conges-
tion. However, in order to significantly improve out-
comes, more research is needed. Patient selection and
timing of Impella support may well be the crucial de-
nominator that decides its effectiveness. To further
optimise patient selection and to overcome hetero-
genic outcomes in future studies on MCS, we suggest
a standard data set of core outcomes and measure-
ments.
Limitations
Eight of the 12 included studies were registries, which
in general have a heterogeneous patient population,
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Study Objective1 Selectioncriteria2
Study
group3 Enrolment
4 Sample
size5 Intervention
6 Confounders7 Outcome8 Statisticalanalysis9
Haemodynamic
measurement10 Overall
11
Meyns [12]
Dens [13]
Seyfarth[14]
Bresson [15]
Griffith [16]
O’Neill [5]
Casassus
[17]
Lima [18]
Schiller [19]
Joseph [20]
Mastroianni
[21]
Hall [22]
1. Was the study question or objective clearly stated?
2. Were eligibility/selection criteria for the study population pre-specified and clearly described?
3. Were the participants in the study representative of those who would be eligible for the test/service/intervention in the general or clinical population of
interest?
4. Were all eligible participants that met the pre-specified entry criteria enrolled?
5. Was the sample size sufficiently large to provide confidence in the findings?
6. Was the test/service/intervention clearly described and delivered consistently across the study population?
7. Were study and patient confounders clearly described? Did the studies take patient and study confounders into account when performing the statistical
analysis?
8. Were the outcome measures pre-specified, clearly defined, valid, reliable, and assessed consistently across all study participants?
9. Did the statistical methods examine changes in outcome measures from before to after the intervention?
10. Were all haemodynamic measurements clearly described as regards time and way of measuring?
11. Final judgement of quality form as regards individual studies.
Yes Moderate No Not reported
Fig. 6 Adapted quality assessment for individual studies according to the U.S. Department of Health and Human Services.
National Heart, Lung and Blood Institute
treatment and outcome. Additionally, 3 out of 12 stud-
ies are from the cVAD (catheter-based ventricular as-
sist devices) registry, owned by Abiomed. Possible
overlap cannot be excluded. When taking these stud-
ies out of the calculation, the overall results remain
the same.
The key hindrance to providing an in-depth meta-
regression analysis at the study level is the great
disparity in the available data reported. Possible
confounding factors are not always reported, includ-
ing the use of vasoactive medication, clinical patient
characteristics and the timing and completeness of
measurements. Although the overall quality of the
studies was considered moderate, all studies showed
a uniform increase in CP(I). This was reflected by an
acceptable heterogeneity score for the overall study
group.
Furthermore, although the intrinsic CP(I) may be
a strong predictor in CS-AMI, this relationship might
be less strong for the CP(I) added by MCS. This dis-
tinction is crucial for adequate interpretation of our
results. In addition, this meta-analysis focuses on the
haemodynamic efficacy in the clinical setting, and
merely reflects whether the pump is effective in in-
creasing output. Procedure- and device-related com-
plications (stroke, access bleeding, infection) are not
included in this study, hampering the true reflection
of clinical benefit for the patient.
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Conclusion
Our meta-analysis shows that short-term MCS with
the Impella device is effective in increasing CP and
CPI. Despite successfully increased CP with Impella
support, the mortality seems to be in line with the
survival rate without Impella use.
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